Authors
Latest:
The Changing Face of Pharma and Biotech Interim ManagementGeoff Newman looks at how pharma and biotech interim management has evolved in the last 20 years.
Latest:
Leveraging Cognitive Search and Search-Based ApplicationsLaurent Fanichet outlines four ways pharma companies can use cognitive search and search-based applications to improve competitiveness.
Latest:
Precision Medicine and Big DataHow integrating next-generation sequencing data can advance efforts in immuno-oncology research.
Latest:
What First Amendment? FDA Remains Unfazed By Off-Label Communication IssuesAn FDA Memo addressing First Amendment legal issues regarding off-label use of medical products falls short of the necessary clarity, write Jamie Kendall and Alexandra Schulz.
Latest:
Addressing eCTDs & New Regulatory Standards for Pharmaceutical Advertising & Promotional MaterialsThomas Christensen outlines some of his lessons learned for first time OPDP submissions, promotional material, and labelling.
Latest:
Securing the Pharma Supply Chain: Current Challenges and Key StepsJeff R. Livingstone outlines the critical steps necessary to ensure an agile, responsive and streamlined supply chain.
Latest:
Improving Customer Engagement: Why Your Data Could Be Letting You DownWhile it is foundational to commercial operations, most European life sciences companies are not getting what they need from their customer data, writes Guillame Roussel.
Latest:
The Doctor is Not In: A Test & Learn Approach to Enhancing the Impact of Non-Personal PromotionIn-market experimentation is the best way to address the challenge of pitching brand leaders on new ways to reach their target population through digital and other non-personal channels, write Scott Beauchamp and Michael Calamari.
Latest:
Price Transparency Regulations are Accelerating Market Disruption. Are You Prepared?As pricing transparency regulations and COVID-19 accelerate market disruption and changes in consumer behavior demand new engagement models, how can your organization prepare for the powerful shift toward more consumer-centric pricing transparency?
Latest:
The Lengthening Arm of PharmacovigilanceExperts debate the practice’s rise up the life sciences agenda.
Latest:
Compliance Regulations in the Trump EraWe know deregulation is coming, although we do not know what it will look like. The one looming question for pharmaceutical and medical device companies is about the future of compliance and regulations.
Latest:
Bracing for Drug Tracing MandatePilot study affirms the value of a standards-based solution for prescription drug traceability-and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.
Latest:
Three Ways President Trump's FDA Can Help Cure CancerCuring cancer is not an impossibility anymore. Essential to any effort to achieve this will be the policies coming from President Trump’s administration, writes James Nathanielsz.
Latest:
Preparing For the New ChinaChina's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt.
Latest:
Why Identity is Imperative for Pharma CompaniesPharma must develop digital identity strategies for creating seamless, safe and compliant customer journeys, writes Jamie Beckland.
Latest:
Marketing During the COVID-19 CrisisAn overview of marketing during the COVID-19 crisis and how to utilize various tactical solutions to successfully reach your targeted healthcare professional audiences.
Latest:
The New Age of BioDigital PharmaIt’s no longer sufficient for a pharma to develop better products or even build simple apps. The industry increasingly needs to create sophisticated predictive algorithms to maximize the ability of its products, write Tom Agan and Fred Geyer.
Latest:
Episode 28: Digital MedicineMichelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.
Latest:
Launch for Long-Term SuccessStudy examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Latest:
Launch for Long-Term SuccessStudy examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Latest:
Launch for Long-Term SuccessStudy examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
